|
Nov 29, 2021
|
BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
|
|
|
Nov 22, 2021
|
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
|
|
|
Nov 12, 2021
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
Nov 05, 2021
|
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)
|
|
|
Nov 03, 2021
|
BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones
|
|
|
Nov 02, 2021
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Nov 01, 2021
|
BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer
|
|
|
Oct 26, 2021
|
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
|
|
|
Oct 20, 2021
|
BioCryst to Report Third Quarter 2021 Financial Results on November 3
|
|
|
Oct 04, 2021
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
